Key information

🔎 Fund Overview

Cortexyme, Inc. is a clinical-stage biopharmaceutical company that is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The company’s pipeline includes a precision bone growth molecule and drug-targeting platform to treat rare skeletal diseases, bone cancer, and injury, in addition to small molecule therapeutics targeting the infectious pathogen P. gingivalis’ role in degenerative disease progression, including for indications such as periodontal disease, oral potentially malignant disorders, and Alzheimer’s disease, among others. Its drug-targeting platform allows the Company to take small molecules, peptides, or large molecules and deliver them directly to the site of disease or injury. The Company's drug candidate, COR388, is an orally administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer's disease. Its COR588 is a second-generation small-molecule lysine-gingipain inhibitor.